Valeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Summary
Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $1.25 for a period of 36 months following the closing of the Offering.The net proceeds from the Offering will be used by the Company for the purposes described in the final short form prospectus of the Company dated June 22, 2021.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. Headquartered in Kirkland, Quebec, Valeo has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.This press release contains certain forward-looking statements regarding the Companys expectations for future events, including statements about the proposed use of net proceeds under the Offering. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.For further information: Steve Saviuk, CEO, 514-693-8830, [email protected]; Luc Mainville, Senior Vice-President and Chief Financial Officer, 514-693-8854, [email protected]; Frederic Dumais, Director, Communications and Investor Relations, 514-782-8803, [email protected]